Tabula Rasa HealthCare (TRHC) falls 0.73% for January 14

Equities Staff  |

Tabula Rasa HealthCare Inc (NASDAQ: TRHC), a Moorestown, New Jersey, company, fell to close at $15.02 Friday after losing $0.11 (0.73%) on volume of 217,565 shares. The stock ranged from a high of $15.06 to a low of $14.37 while Tabula Rasa HealthCare’s market cap now stands at $386,294,979.

About Tabula Rasa HealthCare Inc

Tabula Rasa HealthCare provides medication safety solutions that empower healthcare professionals to optimize medication regimens and reduce medication-related risk, specifically targeting adverse drug events. TRHC's technology solutions, including DoseMeRx™ and MedWise™, improve patient outcomes, reduce hospitalizations, and lower healthcare costs. TRHC's extensive clinical tele-pharmacy network improves care for patients nationwide. Its solutions are trusted by health plans and pharmacies to help drive value-based payment results.

Visit Tabula Rasa HealthCare Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Tabula Rasa HealthCare Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Tabula Rasa HealthCare Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Algoma Steel Upgrades Power Plant in Transition to Green Steelmaking
Insulet Gets FDA Clearance for Omnipod 5 Automated Insulin Delivery System
Russell 2000 Enters Bear Market Territory for First Time in Nearly Two Years
TG Therapeutics Tumbles 40% on Partial Clinical Trial Hold
Huawei Says Carrier Business Stable as Revenues Decline: Jeff Kagan
Time To Reconsider Galapagos as New CEO Paul Stoffels Named
Global Politics Could Drive Extreme Market Volatility in 2022
Stock Stage Sharp Monday Afternoon Rally To Erase Morning Losses



Market Movers

Sponsored Financial Content